Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951165

2024-01-01

Abstract:Supplementary Figure S8. Levels of CAR-T cells and B cells in PB after cell infusion.

What problem does this paper attempt to address?

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951174

2024-01-01

Abstract:Supplementary Figure S5. Characterization of PD-1+ and PD-1- CD4+ T cells in PB and tumor.
Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951162

2024-01-01

Abstract:Supplementary Figure S9. The level of serum cytokines in patients after modified PD-1+ T cell therapy.
Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951168

2024-01-01

Abstract:Supplementary Figure S7. Basic flow chart of PD-1/CD28-CD19 CAR-PD-1+ T cell therapy.
Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951186

2024-01-01

Abstract:Supplementary Figure S1. Construction of PD-1/CD28 receptor, CD19 CAR and PD-1/CD28-T2A-CD19 CAR.
Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951183

2024-01-01

Abstract:Supplementary Figure S2. Quality control of scRNA-seq data.
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Table S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951159

2024-01-01

Abstract:The analysis of modified PD-1+ T cells for patients at each cycle.
Table S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951156

2024-01-01

Abstract:The characteristics of patients with lung cancer for single cell sequencing.
Table S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951150

2024-01-01

Abstract:Characteristics of data for scRNA-seq.
Table S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951153

2024-01-01

Abstract:Characteristics of patients with lung cancer who received anti-PD-1 antibody.
Table S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951138

2024-01-01

Abstract:Treatment-emergent adverse events of patients.
Peripheral blood–derived PD-1/CD28–CD19-CAR–modified PD-1+ T-cell therapy in patients with solid tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.cir-24-0037

IF: 10.1

2024-09-25

Cancer Immunology Research

Abstract:T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction between PD-1+ and PD-1– T cells in terms of clonal overlap. However, CD8+PD-1+ T cells from PB and tumor tissues exhibited tighter clustering based on clone size. Single-cell RNA sequencing analysis showed that PD-1+ T cells from PB highly expressed cytotoxicity-related genes and were enriched for T cell activation–related pathways compared with PD-1– T cells from PB or tumor tissues. Consistent with this, PB-derived PD-1+ T cells exhibited strong cytotoxicity towards autologous tumor cells and tumor cell lines. To augment PD-1+ T-cell activity against solid tumors in vivo, we introduced a PD-1/CD28 fusion receptor combined with a CD19 chimeric antigen receptor (CAR) into PD-1+ T cells, which were then expanded in vitro. The modified PD-1+ T cells exhibited superior proliferation and antitumor abilities in vitro. In addition, four patients with cancer were infused with autologous PD-1/CD28–CD19-CAR PD-1+ T cells. None of these patients experienced severe side effects and one patient with melanoma achieved a complete response that was maintained for 6.7 months. The three other patients had stable disease. Collectively, these results suggested that cell therapy with modified PB-derived PD-1+ T cells is both safe and effective, and it may constitute a promising treatment strategy for cancer patients.

oncology,immunology
Figure S4 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan,Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

DOI: https://doi.org/10.1158/1078-0432.22472427.v1

2023-01-01

Abstract:Supplementary Figure S4. EGFR+ and Ki67+ expression in the complete remission and partial remission patients after CAR T treatment. Immunohistochemistry of CAR T cells (EGFR+, red) and Ki67+ (brown) in tumor samples of the complete remission (CR) and partial remission (PR) patients after CAR T treatment. The cells were counted from five randomly selected visions. Bar plots showing the comparison of absolute quantification of double EGFR+Ki67+ cells.
Figure S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan,Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

DOI: https://doi.org/10.1158/1078-0432.22472433.v1

2023-01-01

Abstract:Supplementary Figure S2. Kinetics of peripheral blood CAR-T cells and serum biomarkers. (A) Bar plots showing the comparison of the peak value (mean {plus minus} SD) and the peak day (median {plus minus} IQR) of CAR T cells in DL1 (purple), DL2 (blue) and DL3 (red). (B) CAR-T cell count (mean {plus minus} SD) change over time from peripheral blood in the CR (green) and PR group (blue). (C) The concentration of serum biomarkers (mean {plus minus} SD) change over time in DL1 (purple), DL2 (blue) and DL3 (red). Student's t-test, one-way ANOVA, Wilcoxon signed-rank test or Friedman test was used, as appropriate. SD: Standard Deviation, IQR: interquartile range.
Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Hui Liu,Wen Lei,Chaoting Zhang,Chunmei Yang,Juying Wei,Qunyi Guo,Xiaojun Guo,Zhilu Chen,Ying Lu,Ken H. Young,Zheming Lu,Wenbin Qian

DOI: https://doi.org/10.1158/1078-0432.23586761.v1

2023-01-01

Abstract:Supplementary Data from CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Figure S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan,Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

DOI: https://doi.org/10.1158/1078-0432.22472436

2023-01-01

Abstract:Supplementary Figure S1. PET-CT and CT evaluation of the partial remission patients before CAR T treatment and on Day 29 after treatment.
Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Chengfei Pu,Liansheng Huang,Yang Su,Tianling Ding,Xibin Xiao,Lina Jin,Zhiyuan Cao,Ting Wu,Tong Chen,Luying Ding,Xiaohong Zhang,Haifeng Lan,Zhao Wu,Lei Xiao

DOI: https://doi.org/10.1158/1538-7445.am2020-lb-379

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e15028 Background: The chimeric antigen receptor (CAR) T cell treatment has been demonstrated as an effective therapy to treat relapsed/refractory B cell malignancy. However, tumor microenvironment influences and affects the efficacy of CAR T treatment. For example, programmed death ligand 1/2 (PDL1/2) may inhibit the CAR T cells via interaction with up-regulated programmed cell death protein 1 (PD1) after T cells activation, suppressing the tumor-killing capability of the CAR T cells. Thus, blockade of the PD1-PDL1/2 interaction may enhance the anti-tumor efficacy of CAR T therapy. Methods: Here, we generated CAR T expressed an anti-CD19 CAR molecule and a dominant-negative PD1 molecule. Compared with conventional CART cells, these “armored” CART cells showed the enhanced capability of tumor-killing and more “memory-like” phenotypes after multiple-round tumor challenging. These results suggest dominant-negative PD1 molecules may protect CART cells from exhaustion in the tumor microenvironment. Results: Further, we reported the findings of a clinical trial for six relapsed or refractory B-cell non-Hodgkin lymphoma (NHLs) patients treated using our armored CAR T cells. These six patients failed multiple rounds of chemotherapy and radiotherapy. In the clinical trial, the patients were infused with autologous CAR T cells range from1×106/kg to 8×106/kg. PET/CT showed significant tumor shrinkage and SUV max declines in all six patients, and the ongoing responses were monitored. The best overall response rate (ORR)was 100%. Conclusions: The results of these six patients in the clinical trial showed that our armored CAR T cells achieved the significant anti-bulky lymphoma response while causing limited and tolerated cytokine release syndrome and central nervous system toxicity. Thus, dominant-negative PD1 molecules may increase CAR T cells persistence in patients, enhancing the efficacy of CAR T cells for treating blood cancer. Finally, dominant-negative PD1 can be used as a platform technology and may be applied to other adoptive cellular immunotherapies such as TCR-T or TIL in the treatment of solid tumors. We are continuing to monitor current patients and recruit more patients for the clinical trial.
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma

Nathan Denlinger,No-Joon Song,Xiaoli Zhang,Hyeongseon Jeon,Chelsea Peterson,Yi Wang,Kelsi Reynolds,Robert Bolz,Jessica Miao,Chunhua Song,Dayong Wu,Wing Keung Chan,Evandro D Bezerra,Narendranath Epperla,Timothy J Voorhees,Jonathan E Brammer,Adam S Kittai,David A Bond,Yazeed Sawalha,Audrey M Sigmund,John C. Reneau,Mark P Rubinstein,Walter Hanel,Beth Christian,Robert A. Baiocchi,Kami J Maddocks,Lapo Alinari,Sumithira Vasu,Marcos de Lima,Dongjun Chung,Samantha M Jaglowski,Zihai Li,Xiaopei Huang,Yiping Yang

DOI: https://doi.org/10.1182/bloodadvances.2023012073

IF: 7.642

2024-03-23

Blood Advances

Abstract:Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized treatment for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Robust biomarkers and a complete understanding of CAR-T cell function in the post-infusion phase remain limited. Here we used a 37-color spectral flow cytometry panel to perform high dimensional single cell analysis of post-infusion samples in 26 patients treated with CD28 co-stimulatory domain containing commercial CAR-T (CD28-CAR-T) for NHL and focused on computationally gated CD8+ CAR-T cells. We found that the presence of post-infusion PD-1+ CD8+ CAR-T cells at the Day 14 timepoint highly correlated with the ability to achieve complete response (CR) by 6 months. Further analysis identified multiple subtypes of CD8+ PD-1+ CAR-T cells including PD-1+ TCF1+ stem-like CAR-T cells and PD-1+ TIM3+ effector-like CAR-T cells that correlated with improved clinical outcomes such as response and progression free survival. Additionally, we identified a subset of PD-1+ CD8+ CAR+ T cells with effector-like function that was increased in patients who achieved a CR and was associated with Grade 3 or higher immune effector cell-associated neurotoxicity syndrome. Here we identified robust biomarkers of response to CD28-CAR-T and highlight the importance of PD-1 positivity in CD8+ CAR-T cells post-infusion in achieving CR.

hematology
Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Mingming Zhang,Linghui Zhou,Houli Zhao,Yanlei Zhang,Guoqing Wei,Ruimin Hong,Wenjun Wu,Huijun Xu,Linqin Wang,Fang Ni,Jiazhen Cui,Shuixiu Peng,Chih-Hua Huang,Alex H. Chang,Yongxian Hu,He Huang

DOI: https://doi.org/10.1158/1078-0432.24952270

2024-01-01

Abstract:Supplementary figure S5 Representative imaging observations before and after CAR-T therapy

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Table S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Table S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Table S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Table S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Table S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Peripheral blood–derived PD-1/CD28–CD19-CAR–modified PD-1+ T-cell therapy in patients with solid tumors

Figure S4 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Figure S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Figure S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma

Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy